We are live on ! Find out more

Thermo Fisher Scientific

TMO

Market cap $241B

651.45 USD

-6.87

1.04%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

651.08

-0.37

0.06%

1 day

-1.04%

5 days

5.94%

1 month

10.6%

3 months

40.21%

6 months

40.19%

Year to date

9.95%

1 year

35.41%

5 years

10.38%

10 years

334.3%

About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Employees: 125,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 43.9%

Neutral 56.1%

Negative 0%

Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year'

Thermo Fisher Scientific NYSE: TMO Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution.

Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year'

Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Here are the stocks to favor in the fourth quarter — and those you should avoid

Large caps tend to outperform small caps as year's end approaches.

Here are the stocks to favor in the fourth quarter — and those you should avoid

Thermo Fisher, Wells Fargo, Nutrien And More On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, picked Horizon Kinetics Inflation Beneficiaries ETF (NYSE:INFL).

Thermo Fisher, Wells Fargo, Nutrien And More On CNBC's ‘Final Trades'

Zacks Investment Research

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks Investment Research

Should You Continue to Hold TMO Stock in Your Portfolio?

Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.

Should You Continue to Hold TMO Stock in Your Portfolio?

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

Why Moderna's Cancer Vaccine Matters to Investors

Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification, enzyme-linked immunosorbent assays (ELISAs), cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Laboratories performing absorbance-based analysis are under increasing pressure to generate reliable data.

Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis

Zacks Investment Research

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 9:15 a.m. (ET).You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com.About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leade.

Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026

See News Rankings

Price charts implemented using Lightweight Charts™